Michael Ackermann

Chairman, Oyster Point Pharmaceuticals, Inc.; Chairman, Tarsus Pharmaceuticals, Inc.; CEO, Presidio Medical, Inc.


Michael Ackermann is the Chairman of Oyster Point Pharmaceuticals, Inc., Chairman of Tarsus Pharmaceuticals, Inc. and CEO of Presidio Medical, Inc. Michael is also a member of the teaching faculty at Stanford University’s Biodesign graduate program. Prior, Michael served as Vice President, Neurostimulation for Allergan plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan in August 2015. He received a bachelor’s degree in biomedical engineering from Vanderbilt University, M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University, and is a graduate of the Stanford University Biodesign Fellowship and the Vision Research Fellowship at Stanford.